GT Biopharma is trading 19% down at $9.46 after a highly volatile speculative run.
- It previously gained 35.08% on September 14 and 39.32% on September 11.
- No confirmed company-specific catalyst explaining the September 15 decline was identified; the September 8 reverse split and September 11 TriKE® presentation are earlier developments.
- Broader markets are only modestly lower and do not clearly explain the move.